CACHEMIR

SATT NORD
Technology Transfer Office

Personalized medicine, improves response rate to cisplatin in patients with non-small cell lung cancer

Keywords

- NSCLC
- miRNA
- LNA-oligonucleotide
- Personalized medecine
- Biomarker

Intellectual Property

EP 16306563.4
priority date : 25th of november 2016

Development Status

Therapeutic:
POC in vitro & in vivo upcoming

Diagnosis:
Validation of the predictive biomarker upcoming

Partnership

Out-licensing or Partnerships

Technology

The miRNA research field is of interest for the future and is now well established that miRNAs represent new potential therapeutic targets as well as relevant diagnostic / prognostic biomarkers.

Nearly 60% of patients with non-small cell lung cancer are resistant to cisplatin, a first-line anti-cancer agent.

The research teams in this project have identified a specific miRNA as a genetic factor involved in these resistances.

miR-X is both a biomarker that can predict resistance to chemotherapy and a new therapeutic target allowing combined treatment against lung cancer.



Benefits

- Diagnosis: Predictive biomarker of response for patients treated with cisplatin allowing a dedicated treatment. Biomarker monitoring the effectiveness of this same treatment.
- Therapeutic: Improved response rate to cisplatin in patients with non-small cell lung cancer.

Applications

- Personalized medecine
- Non-small cell lung cancer

contact

Yannick Campion
Business Developer
+33 6 13 84 38 04
Yannick.campion@sattnord,fr

find other technologies on
www.sattnord.fr

SATT Nord
25, avenue Charles St Venant – 59800 LILLE – France
+33 3 28 36 04 68 – tech@sattnord.fr

membre SATT Réseau

Reference CACHEMIR-01/2017-v1.0